Drugs / ebenatide
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05990374 Comparator | Aug 2023 → Jan 2024 | type 2 diabetes mellitus | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ebenatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05990374 ↗ |
| Modality | Peptide | “AIM: Investigate effects of Ebenatide, a novel glucagon-like peptide-1 analogue, on glycemic control and body composition in type 2 diabetes mellitus (T2DM).” PMID 40607222 ↗ Jun 2025 |